From January 5-6, 2024, the "Northern Breast Cancer Salon Annual Review and 2024 CSCO BC Guidelines Update Discussion" was held in Beijing. During the session on "Targeted Treatment-TNBC," Professor Qiang Liu from Sun Yat-sen Memorial Hospital of Sun Yat-sen University presented a report on "Progress in the Treatment of Early Triple-Negative Breast Cancer (TNBC)." After the session, "Oncology Frontier" conducted an exclusive interview with Professor Liu on the treatment of patients with early TNBC. The detailed content is organized below.

Bipolar Androgen Therapy (BAT) is an emerging treatment for metastatic castration-resistant prostate cancer (mCRPC) that significantly reduces prostate-specific antigen (PSA) levels in some patients, improves their quality of life, and restores sensitivity to castration treatments. This therapy has shown great potential in the treatment of mCRPC patients. On January 6, 2024, the "2024 Beijing Urological Tumors Youth Forum," co-hosted by the Beijing Cancer Fighting Association’s Young Committee for Urological Malignancies and the Beijing Medical Award Foundation, was successfully held in Beijing. Professor Ming Liu, Head of Urology at Beijing Hospital, delivered an insightful presentation titled "Early Experiences with Sequential Bipolar Androgen Therapy Combined with PD-1 Treatment in mCRPC," and discussed the concept and progress of BAT in an interview with "Oncology Frontier."

Large B-cell lymphoma (LBCL) is a common malignant hematologic disorder, representing 40% of all new non-Hodgkin lymphoma diagnoses. About 60% of patients respond to first-line standard immunotherapy, but the prognosis for high-risk patients is generally poor. Recently, chimeric antigen receptor T-cell (CAR-T) therapy has demonstrated controllable safety and significant efficacy in the treatment of relapsed/refractory B-cell lymphomas, including LBCL, follicular lymphoma (FL), and mantle cell lymphoma (MCL). The 50th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting took place in Glasgow, UK, from April 14th to 17th, 2024. During the conference, American researcher Alejandro Luna de Abia presented a retrospective study (Abstract No.: OS6-06) indicating that extranodal involvement significantly impacts the prognosis of LBCL patients undergoing CAR-T therapy, highlighting the need for personalized management strategies for these patients. “Oncology Frontier - Hematology Frontier” has invited Professor Liang Huang from the Institute of Hematology, Chinese Academy of Medical Sciences, to provide a comprehensive review of this study.

Breast cancer is one of the most common malignant tumors among women. Influenced by various factors, the incidence of breast cancer has been increasing year by year. With the addition of immunotherapy and targeted therapy, more breast cancer patients see hope for treatment. "Oncology Frontier" specially invited Professor Cuizhi Geng from The Fourth Hospital of Hebei Medical University to discuss the current state of diagnosis and treatment of breast cancer in China and the future directions for exploration in this field.

With the rapid advancements in the field of urologic oncology in China, an increasing number of Chinese studies are making their mark on the global stage. At the recent 39th European Association of Urology Annual Meeting (EAU24) held in Paris, France, Professor Gong Kan's team from Peking University First Hospital presented several new research findings. At the event, Dr. Zhang Zedan and Dr. Deng Ruiyi from Professor Gong’s team were invited by the journal "Oncology Frontier" to share their latest studies.

From April 14 to 17, 2024, the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Glasgow, marking the 50th anniversary of EBMT. This event gathered leaders in hematopoietic stem cell transplantation and over 6,000 hematology experts worldwide to reflect on the extraordinary achievements in the field over the past half-century and to explore future patient management strategies. At the conference, Professor He Huang from the First Affiliated Hospital of Zhejiang University College of Medicine shared significant advancements in novel cellular immunotherapies, capturing the attention of many. This publication has invited Professor Huang for an in-depth interview to discuss the innovations in the field of cellular immunotherapy.

Based on the CheckMate -274 study, nivolumab became the world's first approved immunotherapy for adjuvant treatment of urothelial carcinoma, while the IMvigor 010 did not achieve positive DFS results, leading to the subsequent focus on ctDNA (MRD) positive patients in the IMvigor 011 study. At the recent 2024 ASCO-GU conference, the results of the pembrolizumab adjuvant therapy AMBASSADOR study were reported. This study uniquely set both DFS and OS as dual endpoints, achieving positive results for DFS, though the control group's receipt of immunotherapy may impact the OS endpoint. "Oncology Frontier" interviewed the study's presenter, Professor Andrea B. Apolo from the National Cancer Institute (NCI), at the conference.